EUCTR2017-004376-64-SE进行中（未招募）1 期
A Phase I/II, randomised, multicentre, placebo-controlled, partially-blinded, parallel-group study to assess the safety, tolerability and immune response following vaccination with ImmunoseTM FLU in older adults (age 50 to 75 years)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Signed informed consent prior to any study related procedures.
- •2.Male or female 50-75 years of age (both inclusive) at screening.
- •3.Subjects who the Investigator believes will comply with the requirements of the protocol.
- •4.Judged by the Investigator to have no serious illness based on medical history, physical examination, ECG, vital signs and blood and urine assessments at screening.
- •5.All females should have been post-menopausal for at least 12 months or use a highly effective contraceptive method to prevent pregnancy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •1.Diagnosis of laboratory-confirmed influenza in the 2017/2018 season.
- •2.Use of any investigational drug product within 3 months before screening or planned use during the study period, including the safety follow-up period.
- •3.Administration of an influenza vaccine during the 9 months before screening.
- •4.Previously received another vaccine within 28 days before administration of the study vaccine, or is scheduled to receive another vaccine during the study period, excluding the safety follow-up period.
- •5.Any contra-indication to intramuscular administration of the influenza vaccine Influsplit Tetra (Fluarix Tetra) according to its SPC.
- •6.History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to eggs or egg product as well as ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin, gentamycin, neomycin sulphate, formaldehyde and sodium deoxycholate).
- •7.Diagnosis of asthma with poor disease control as assessed by the Investigator.
- •8.Potent immunosuppressive therapy including cytostatics, antibodies, drugs acting on immunophilins, interferons and other drugs used to prevent rejection of organ transplants, within 6 months before screening.
- •9.Use of any parenteral or oral corticosteroids within 30 days prior to screening. Inhaled steroids are allowed.
- •10.Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •11.Any progressive or severe neurologic disorder, seizure disorder or Guillain-Barré syndrome.
- •12.Any history of Guillain-Barré syndrome.
- •13.Received blood, blood products and/or plasma derivatives or any administration of immunoglobulin preparation within the 3 months prior to Visit 2, or planned during the study.
- •14.Participation in blood donation within 3 months or plasma donation within 1 month prior to Visit 2.
- •15.History of substance or alcohol abuse within the past 2 years.
- •16.History or any illness/condition that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
- •17.Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody or HIV.
- •18.Pregnant or lactating female or intent to become pregnant during the clinic phase and for 2 months after the last vaccination.
- •19.History of Bell’s palsy.
- •20.Ongoing regular use of intranasal sprays including corticosteroids and decongestants.
- •21.Ongoing cough, sinusitis, allergic rhinitis, nasal polyps or obstruction, including septum deviation significant enough to prevent bilateral administration of study vaccine.
- •22.Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- •23.Subjects that are prone to nosebleed.
研究者
相似试验
进行中（未招募）
1 期
A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladderA phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladderMedDRA version: 8.1Level: LLTClassification code 10059617EUCTR2005-005457-22-CZTanabe Seiyaku Co., Ltd225
进行中（未招募）
1 期
A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladderA phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladderMedDRA version: 8.1 Level: LLT Classification code 10059617EUCTR2005-005457-22-GBTanabe Seiyaku Co., Ltd225
进行中（未招募）
不适用
A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladderA phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladderMedDRA version: 8.1Level: LLTClassification code 10059617EUCTR2005-005457-22-HUTanabe Seiyaku Co., Ltd225
进行中（未招募）
不适用
A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladderEUCTR2005-005457-22-FITanabe Seiyaku Co., Ltd225
进行中（未招募）
不适用
A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladderEUCTR2005-005457-22-SETanabe Seiyaku Co., Ltd225